Metabolic syndrome and its factors affect cognitive function in chronic schizophrenia complicated by metabolic syndrome

Journal of Nervous and Mental Disease

Volumn 202, Issue 4, 2014, Pages 313-318

  Li, Chenhu ^a   Zhan, Guilai ^a   Rao, Shunzeng ^a   Zhang, Hong ^a  

^a SHANGHAI MENTAL HEALTH CENTER   (China)

Author keywords

Cognitive function; Metabolic syndrome; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATTENTION; CLINICAL ASSESSMENT TOOL; COGNITIVE DEFECT; CROSS-SECTIONAL STUDY; EDUCATIONAL STATUS; FEMALE; HUMAN; LANGUAGE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; POSITIVE AND NEGATIVE SYNDROME SCALE; PREVALENCE; RATING SCALE; REPEATABLE BATTERY FOR THE ASSESSMENT OF NEUROPSYCHOLOGICAL STATUS; SCHIZOPHRENIA; SCORING SYSTEM; SHORT TERM MEMORY; SKILL; SYSTOLIC BLOOD PRESSURE; TREATMENT EMERGENT SYMPTOM SCALE;

ADULT; CHRONIC DISEASE; COGNITION DISORDERS; COMORBIDITY; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA;

EID: 84897580331     PISSN: 00223018     EISSN: 1539736X     Source Type: Journal    
DOI: 10.1097/NMD.0000000000000124     Document Type: Article

References (29)

1. Al-Aqeedi RF, Abdullatef WK, Dabdoob W, Bener A, Albinali HA, Gehani A (2013) The prevalence of metabolic syndrome components, individually and in combination, in male patients admitted with acute coronary syndrome, without previous diagnosis of diabetes mellitus. Libyan J Med. 8:20185.
2. Cavali Mde L, Escrivao MA, Brasileiro RS, Taddei JA (2010) Metabolic syndrome: Comparison of diagnosis criteria. J Pediatr (Rio J). 86:325-330.
3. Collins AA, Remington GJ, Coulter K, Birkett K (1997) Insight, neurocognitive function and symptom clusters in chronic schizophrenia. Schizophr Res. 27:37-44.
4. Cruz BF, Resende CB, Abreu MN, Rocha FL, Teixeira AL, Keefe RS, Salgado JV (2013) How specific are negative symptoms and cognitive impairment in schizophrenia?. An analysis of PANSS and SCoRS. Cogn Neuropsychiatry. 18:243-251.
5. De Hert M, Mauri M, Shaw K, Wetterling T, Doble A, Giudicelli A, Falissard B (2010) The METEOR study of diabetes and other metabolic disorders in patients with schizophrenia treated with antipsychotic drugs. I. Methodology. Int J Methods Psychiatr Res. 19:195-210.
6. De Hert MA, van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, Peuskens J (2006) Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res. 83:87-93.
7. Dekker JJ, Theunissen J, Van R, Peen J, Duurkoop P, Kikkert M (2010) Victimization of patients with severe psychiatric disorders: Prevalence, risk factors, protective factors and consequences for mental health. A longitudinal study. BMC Public Health. 10:687.
8. Donders J, DenBraber D, Vos L (2010) Construct and criterion validity of the Behaviour Rating Inventory of Executive Function (BRIEF) in children referred for neuropsychological assessment after paediatric traumatic brain injury. J Neuropsychol. 4:197-209.
9. Friedman JI, Wallenstein S, Moshier E, Parrella M, White L, Bowler S, Gottlieb S, Harvey PD, McGinn TG, Flanagan L, Davis KL (2010) The effects of hypertension and body mass index on cognition in schizophrenia. Am J Psychiatry. 167:1232-1239.
10. Guse B, Falkai P, Gruber O, Whalley H, Gibson L, Hasan A, Obst K, Dechent P, McIntosh A, Suchan B, Wobrock T (2013) The effect of long-Term high frequency repetitive transcranial magnetic stimulation on working memory in schizophrenia and healthy controlsVA randomized placebo-controlled, doubleblind fMRI study. Behav Brain Res. 237:300-307.
11. Harvey KE, Galletly CA, Field C, Proeve M (2009) The effects of verbalisation on cognitive performance in schizophrenia: A pilot study using tasks from the Delis Kaplan Executive Function System. Neuropsychol Rehabil. 19:733-741.
12. Karanauskaite J, Hoppa MB, Braun M, Galvanovskis J, Rorsman P (2009) Quantal ATP release in rat beta-cells by exocytosis of insulin-containing LDCVs. Pflugers Arch. 458:389-401.
13. King LC, Bailie JM, Kinney DI, Nitch SR (2012) Is the Repeatable Battery for the Assessment of Neuropsychological Status factor structure appropriate for inpatient psychiatry?. An exploratory and higher-order analysis. Arch Clin Neuropsychol. 27:756-765.
14. Lee NY, Kim SH, Jung DC, Kim EY, Yu HY, Sung KH, Kang UG, Ahn YM, Kim YS (2011) The prevalence of metabolic syndrome in Korean patients with schizophrenia receiving a monotherapy with aripiprazole, olanzapine or risperidone. Prog Neuropsychopharmacol Biol Psychiatry. 35:1273-1278.
15. Marcos B, Aisa B, Ramirez MJ (2008) Functional interaction between 5-HT(6) receptors and hypothalamic-pituitary-Adrenal axis: Cognitive implications. Neuropharmacology. 54:708-714.
16. Meyer JM, Stahl SM (2009) The metabolic syndrome and schizophrenia. Acta Psychiatr Scand. 119:4-14.
17. Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M (2013) Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disordersVA systematic review and meta-Analysis. Schizophr Bull. 39:306-318.
18. Mohamed S, Paulsen JS, O'Leary D, Arndt S, Andreasen N (1999) Generalized cognitive deficits in schizophrenia: A study of first-episode patients. Arch Gen Psychiatry. 56:749-754.
19. Moore RC, Davine T, Harmell AL, Cardenas V, Palmer BW, Mausbach BT (2013) Using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) effort index to predict treatment group attendance in patients with schizophrenia. J Int Neuropsychol Soc. 19:198-205.
20. Napal O, Ojeda N, Elizagarate E, Pena J, Ezcurra J, Gutierrez M (2012) The course of the schizophrenia and its impact on cognition: A review of literature. Actas Esp Psiquiatr. 40:198-220.
21. Nasrallah HA (2010) Linkage of cognitive impairments with metabolic disorders in schizophrenia. Am J Psychiatry. 167:1155-1157.
22. Panza F, Frisardi V, Capurso C, Imbimbo BP, Vendemiale G, Santamato A, D'Onofrio G, Seripa D, Sancarlo D, Pilotto A, Solfrizzi V (2010) Metabolic syndrome and cognitive impairment: Current epidemiology and possible underlying mechanisms. J Alzheimers Dis. 21:691-724.
23. Pilla Reddy V, Kozielska M, Johnson M, Suleiman AA, Vermeulen A, Liu J, de Greef R, Groothuis GM, Danhof M, Proost JH (2012) Modelling and simulation of the Positive and Negative Syndrome Scale (PANSS) time course and dropout hazard in placebo arms of schizophrenia clinical trials. Clin Pharmacokinet. 51:261-275.
24. Puig MV, Artigas F, Celada P (2005) Modulation of the activity of pyramidal neurons in rat prefrontal cortex by raphe stimulation in vivo: Involvement of serotonin and GABA. Cereb Cortex. 15:1-14.
25. Raffaitin C, Feart C, Le Goff M, Amieva H, Helmer C, Akbaraly TN, Tzourio C, Gin H, Barberger-Gateau P (2011) Metabolic syndrome and cognitive decline in French elders: The Three-City Study. Neurology. 76: 518-525.
26. Semkovska M, Bedard MA, Stip E (2001) Hypofrontality and negative symptoms in schizophrenia: Synthesis of anatomic and neuropsychological knowledge and ecological perspectives [in French]. Encephale. 27:405-415.
27. Tuulio-Henriksson A, Perala J, Saarni SI, Isometsa E, Koskinen S, Lonnqvist J, Suvisaari J (2011) Cognitive functioning in severe psychiatric disorders: A general population study. Eur Arch Psychiatry Clin Neurosci. 261:447-456.
28. Waddington JL, Buckley PF, Scully PJ, Lane A, O'Callaghan E, Larkin C (1998) Course of psychopathology, cognition and neurobiological abnormality in schizophrenia: Developmental origins and amelioration by antipsychotics?. J Psychiatr Res. 32:179-189.
29. Yang C, Winkelman JW (2006) Clinical significance of sleep EEG abnormalities in chronic schizophrenia. Schizophr Res. 82:251-260.